Novartis exec moves to J&J
Executive Summary
Head of Novartis' North American pharmaceuticals unit Alex Gorsky resigns, the firm announces Feb. 14. Gorsky will join Johnson & Johnson as group chairman of the firm's medical device company Ethicon. Before joining Novartis in 2004 as Chief Operating Officer and Head of General Medicines, Gorsky served as company group chairman for J&J's pharmaceutical business in Europe, the Middle East and Africa. Gorsky will report to J&J Worldwide Chairman for Surgical Care Sheri McCoy...
You may also be interested in...
Novartis North America pharma head
Ludwig Hantson becomes head of Novartis' North America pharma business, the company announces April 10. Hantson, who led Novartis' Specialty Medicines Operating Unit, replaces Alex Gorsky effective immediately (1"The Pink Sheet," Feb. 25, 2008, In Brief). Among other challenges, Hantson will have to determine the best course of action for Novartis' DPP-4 inhibitor Galvus (vildagliptin) following an approvable letter in 2007
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.